ArticleNature2020
A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 213 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed, 2 pooled it
21.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
213 citing papers in PubMed, 2 syntheses or guidelines pooled it, 305 citations in OpenAlex.
- ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dubé syndrome.European journal of human genetics : EJHG · 2024Guideline
- A Possible Association of Salivary Gland Tumors and Oral Lesions with Birt-Hogg-Dube Syndrome: A Systematic Review.Head and neck pathology · 2024Pooled it
- Substrate-specific regulation of the mTORC1 pathway by G protein-coupled receptors.The Biochemical journal · 2026Article
- Noncanonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma.The Journal of clinical investigation · 2026Article
- Synergistic role of TFEB/TFE3 and mTORC1 in kidney cystogenesis and tumorigenesis.Cell death and differentiation · 2026Article
- Pathogenic mutations in ATAD3A cause dysregulation of RagC/D-TFEB axis and disrupt lysosomal homeostasis.bioRxiv : the preprint server for biology · 2026Article
- mTORC1-TFEB/TFE3 signaling is associated with bile acid diversification during hepatic metabolic adaptation.Science advances · 2026Article
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivation.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Aggressive high-grade papillary-patterned renal cell carcinomas harboring FLCN mutations: expanding the clinicopathological spectrum in Birt-Hogg-Dubé syndrome and sporadic cases.Virchows Archiv : an international journal of pathology · 2026Article
- Dietary protein governs the role of insulin signaling in the postprandial regulation of hepatic mTORC1.Nature communications · 2026Article
- Lysosomes and lysosomal dysfunction in ageing biology.Nature cell biology · 2026Review
- Global cellular responses to lysosomal damage.Current biology : CB · 2026Review
- TMEM175 rescues post-infarct cardiac dysfunction via mTORC1-lysosomal axis modulation.Acta pharmacologica Sinica · 2026Article
- Diagnostic utility of novel marker TRIM63 ISH in the workup of uterine perivascular epithelioid cell tumors.Virchows Archiv : an international journal of pathology · 2026Article
- Parotid Oncocytomas Express the Glycoprotein Non-metastatic Melanoma Protein B (GPNMB): A Potential Link with Birt-Hogg-Dubé Syndrome.Head and neck pathology · 2026Article
- AMPK promotes TFEB transcriptional activity through dephosphorylation at both MTORC1-dependent and -independent sites.Autophagy · 2026Article
- Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine-ZBTB5-mTORC1 axis.Nature cell biology · 2026Article
- Integrative In Silico mRNA-miRNA Profiling of mTOR Pathway Dysregulation in High-Grade Serous Ovarian Carcinoma.Cancers · 2026Article
153 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 6 institutions in 3 countries.
Gennaro Napolitano *Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Chiara Di Malta *Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Alessandra EspositoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Mariana E G de AraujoInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-0576-2680
Salvatore PeceIEO, European Institute of Oncology IRCCS, Milan, Italy.
Giovanni BertalotIEO, European Institute of Oncology IRCCS, Milan, Italy.
Maria MatareseTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Valerio BenedettiTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Angela ZampelliTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Taras StasykInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Diletta SicilianoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Alessandro VenutaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Marcella CesanaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Claudia VilardoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Edoardo NuscoTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Jlenia MonfregolaTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Alessia CalcagnìDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1946-5815
Pier Paolo Di FioreIEO, European Institute of Oncology IRCCS, Milan, Italy.
Lukas A HuberInstitute of Cell Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-1116-2120
Andrea BallabioTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy. ballabio@tigem.it.ORCID http://orcid.org/0000-0003-1381-4604
Telethon Institute Of Genetics And Medicine · ITInnsbruck Medical University · ATBaylor College of Medicine · USUniversity of Milan · ITEuropean Institute of Oncology · ITFederico II University Hospital · IT
Funding
MODULATION OF CELLULAR CLEARANCE TO TREAT HUMAN DISEASER01NS078072 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI BALLABIO, ANDREA · 2012 to 2020
$3.1MEuropean Research Council 694282NINDS NIH HHS R01 NS078072
Abstract
The mechanistic target of rapamycin complex 1 (mTORC1) is a key metabolic hub that controls the cellular response to environmental cues by exerting its kinase activity on multiple substrates
Indexed as
AnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBirt-Hogg-Dube SyndromeCell LineDisease Models, AnimalEnzyme ActivationHeLa CellsHumansKidney NeoplasmsMechanistic Target of Rapamycin Complex 1MiceMice, KnockoutMonomeric GTP-Binding ProteinsPhosphorylationProtein BindingProto-Oncogene ProteinsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBhd protein, mouseMechanistic Target of Rapamycin Complex 1Monomeric GTP-Binding ProteinsProto-Oncogene ProteinsRas Homolog Enriched in Brain ProteinRHEB protein, humanRRAGC protein, humanRRAGD protein, humanTcfeb protein, mouseTFEB protein, humanTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.